Prolonged use of bedaquiline in the treatment for MDR-TB in a child.

Bedaquiline (Bdq), a novel TB drug, is referred to the most effective drugs and used for the management of multidrug-resistant tuberculosis (MDR-TB). The drug produces a cardiotoxic effect, and its use is limited to six months. We describe a clinical observation of prolonged bedaquiline use in the treatment for MDR-TB using a restricted number of drugs, to which susceptibility was preserved, in a 12-year-old child.

[Role of specific immunoglobulins of classes G, E and subclasses G1, G4 in the diagnosis of tuberculosis in children with hyperergic tuberculin sensitivity].

The study covered 56 patients (aged 6-14 years) having hyperergic tuberculin sensitivity, including 28 patients with pulmonary tuberculosis (Group 1) and 28 patients infected with Mycobacterium tuberculosis (MBT) (Group 2). All tuberculous processes were asymptomatic and limited. Minor forms of tuberculosis, diagnosed by computed tomography, were found in 71.

[Experience with a differential approach to treating mild forms of intrathoracic tuberculosis in children].

The authors present their experience in applying a differential approach to treating mild forms of tuberculosis in children. They analyzed 40 case histories of tuberculosis risk-group children in whom computed tomography revealed changes in the lung or intrathoracic lymph nodes. Twenty-one children who had been diagnosed as having active tuberculosis on the first examination were treated by the 2 HRZ/4 HZ regimen.

[Clinical and X-ray characteristics of first detected intrathoracic lymph node tuberculosis in children].

Sixty-two case histories of Moscow children aged 4-12 years, treated at the Central Research Institute of Tuberculosis, Russian Academy of Medical Sciences, for first detected intrathoracic lymph node tuberculosis (ITLNT), were studied. Planned and prophylactic studies revealed the disease in 95.1% (including 66.